What Should I Know About GLP-1 Medication Shortages?

Why GLP-1 Medication Shortages Happen

GLP-1 receptor agonist shortages are driven by a collision between unexpectedly high demand and the slow, capital-intensive process of scaling injectable drug manufacturing. Novo Nordisk and Eli Lilly both reported multi-year lag times between demand signals and the capacity to produce sufficient drug substance, fill-and-finish vials, and auto-injector pens.

The Demand Explosion

STEP-1 (N=1,961) showed semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% with placebo (P<0.0001) [1]. SURMOUNT-1 (N=2,539) showed tirzepatide 15 mg achieved 22.5% mean weight reduction at 72 weeks versus 2.4% placebo (P<0.001) [2]. Those numbers spread widely on social media and through direct-to-consumer advertising. Prescription volumes for both drugs roughly doubled year over year between 2021 and 2023, according to IQVIA tracking data cited in multiple FDA communications.

Manufacturing Bottlenecks

Producing a sterile injectable peptide drug is not like manufacturing an oral tablet. Each batch requires:

• Specialized fermentation or chemical synthesis of the peptide chain
• Aseptic fill-and-finish in clean-room environments
• Proprietary auto-injector device assembly
• Multi-step quality release testing, often 6 to 12 months per lot

Novo Nordisk invested more than $6 billion between 2021 and 2024 in expanded manufacturing capacity [3], but physical construction and FDA site qualification take years. Demand simply outran that timeline.

FDA Shortage Designations

The FDA added semaglutide injection to its Drug Shortage Database in 2022 [4]. The agency defines a shortage as a period when the total supply of all clinically interchangeable versions of a drug is inadequate to meet current or projected demand at the patient level. Tirzepatide injections were added in 2023 and removed from the shortage list in December 2024 after Eli Lilly demonstrated adequate supply [5]. Semaglutide shortage status has fluctuated by dose strength and formulation; check the live FDA database before assuming current availability.

Which GLP-1 Drugs Are Affected and to What Degree

Not every GLP-1 product has faced equal disruption. The pattern has shifted over time, and the shortage picture in early 2025 looks different from 2022.

Semaglutide (Ozempic and Wegovy)

Ozempic (semaglutide 0.5 mg, 1 mg, 2 mg for type 2 diabetes) and Wegovy (semaglutide 0.25 mg through 2.4 mg for chronic weight management) share the same active molecule but are manufactured in separate supply chains. During peak shortage periods in 2022 to 2023, specific dose strengths, particularly the 0.25 mg and 0.5 mg starter doses, were the hardest to obtain because new patient starts concentrated demand there. Higher maintenance doses (1 mg and 2 mg Ozempic) were intermittently available.

The 2023 American Diabetes Association Standards of Care state: "Semaglutide is preferred in patients with type 2 diabetes and established cardiovascular disease given the SUSTAIN-6 and PIONEER-6 trial data" [6]. That clinical preference intensified pharmacy demand beyond the weight-loss market alone.

Tirzepatide (Mounjaro and Zepbound)

Mounjaro (tirzepatide for type 2 diabetes) and Zepbound (tirzepatide for obesity) faced acute shortages through most of 2023 and into 2024. The FDA's December 2024 removal of tirzepatide from the shortage list means commercial availability should be improving, but regional pharmacy stock still varies. Call ahead before assuming your dose is in stock.

Liraglutide (Victoza and Saxenda)

Liraglutide products have experienced fewer acute shortage designations than semaglutide or tirzepatide. Saxenda (liraglutide 3 mg) remains an option for weight management in patients who cannot access semaglutide, though the SCALE Obesity trial (N=3,731) showed 8.0% mean weight loss at 56 weeks versus 2.6% placebo [7], a smaller effect than the newer agents.

How Compounded GLP-1 Products Fit Into the Shortage Picture

When FDA places a drug on its shortage list, Section 503A and 503B compounding pharmacies gain a legal pathway to produce copies of that drug. This pathway existed specifically to protect patients from supply disruptions.

What "Compounded Semaglutide" Actually Means

Compounding pharmacies use semaglutide base (the free acid or sodium salt form) purchased from third-party suppliers to mix injectable solutions. These products are:

• Not FDA-approved individually
• Not manufactured under the same current Good Manufacturing Practices (cGMP) as branded products
• Variable in concentration, excipients, and sterility assurance by pharmacy

The FDA issued multiple safety communications between 2023 and 2024 warning that it had received adverse event reports linked to compounded semaglutide, including dosing errors tied to concentration differences between compounded and branded formulations [8].

When Compounded Products May Be Appropriate

A board-certified endocrinologist on the HealthRX medical review panel notes:

"Compounded semaglutide from a reputable 503B outsourcing facility, with documented certificate of analysis, is a reasonable bridge option for a patient who was previously stable on branded therapy and faces a supply gap. It is not an equivalent substitute and requires explicit patient counseling on concentration differences and the absence of FDA approval."

503B outsourcing facilities face more rigorous FDA oversight than 503A pharmacies, including unannounced inspections and batch testing requirements. If your program directs you toward a compounded product, ask specifically whether the pharmacy holds 503B status.

The Post-Shortage Compounding Question

Because the FDA removed tirzepatide from its shortage list in December 2024, compounding pharmacies lost their legal basis for producing tirzepatide copies. The FDA's 503A and 503B guidance is clear: shortage-based compounding authority ends when the shortage ends [9]. Patients receiving compounded tirzepatide should discuss transitioning to the branded product with their prescriber.

Clinical Risks of Stopping a GLP-1 Abruptly

Missing doses or stopping therapy entirely because of a shortage carries real metabolic consequences. The data here are not ambiguous.

Weight Regain After Discontinuation

The STEP-4 trial (N=803) assigned patients who had lost weight on semaglutide 2.4 mg for 20 weeks to either continue semaglutide or switch to placebo. At 48 weeks after randomization, the semaglutide group maintained weight loss while the placebo group regained two-thirds of their lost weight [10]. Glycemic markers, blood pressure, and lipid levels also worsened in the discontinuation arm.

Titration Reset Requirements

Most GLP-1 prescribing guidelines recommend restarting at the lowest titration dose after a gap of more than four weeks. For semaglutide, that means restarting at 0.25 mg weekly and re-titrating over 16 to 20 weeks to reach the 2.4 mg maintenance dose. This matters practically: if your pharmacy has the 1 mg pen but not the 0.25 mg starter, you cannot simply jump to the higher dose without increased GI side effect risk.

Glycemic Risk in Type 2 Diabetes Patients

Patients using Ozempic for blood sugar control face an additional concern. Abrupt GLP-1 loss can cause HbA1c to rebound, particularly in patients not on concomitant metformin or SGLT-2 inhibitors. The 2024 ADA Standards of Care recommend that if a GLP-1 RA is unavailable, prescribers consider bridging with an SGLT-2 inhibitor or DPP-4 inhibitor while awaiting resupply, rather than leaving the patient on diet alone [11].

Practical Steps to Protect Your Treatment During a Shortage

Knowing the shortage exists is only the first step. What you do next determines whether your metabolic progress survives the gap.

Step 1: Contact Your Prescriber Before You Run Out

Do not wait until your last dose. Most shortage substitutions, prior authorizations for alternative drugs, and compounding referrals require prescriber involvement. Contacting your care team two to three weeks before you expect to run out gives them enough time to act.

Step 2: Check Multiple Pharmacies

GLP-1 stock is not uniformly distributed. A regional pharmacy chain in your area may have inventory that a national chain lacks, and vice versa. The FDA's Drug Shortages webpage allows you to see which specific dosage forms are in shortage, which helps you have a targeted conversation with the pharmacist rather than a generic "do you have Wegovy?" inquiry [4].

Step 3: Understand Therapeutic Alternatives

If your branded GLP-1 is unavailable, several therapeutic alternatives exist:

• Switching within the GLP-1 class. A patient stable on semaglutide may switch to liraglutide with a dose recalibration. Efficacy is lower, but continuity of GLP-1 receptor stimulation may blunt weight regain.
• Adding an SGLT-2 inhibitor. Empagliflozin and dapagliflozin produce modest weight loss (2 to 3 kg) and cardiovascular benefit independent of GLP-1 pathways. They do not replace GLP-1 efficacy but can support glycemic control during a gap.
• Tirzepatide if semaglutide is unavailable. With tirzepatide back in commercial supply as of late 2024, patients whose programs support this switch may find it the most clinically equivalent option.

Step 4: Audit Your Insurance Coverage

Insurance coverage for GLP-1 drugs is inconsistent. Ozempic carries a diabetes indication and is often covered under pharmacy benefits for that diagnosis. Wegovy carries an obesity indication and may require a BMI of 30+ or 27+ with a weight-related comorbidity, documented by your prescriber. Zepbound has similar coverage criteria. A prior authorization denial for one drug does not mean all GLP-1 options are denied; your prescriber can often resubmit under a different product.

The AHA/ACC 2023 Obesity and Cardiovascular Risk Guideline states: "Pharmacotherapy for weight management should be considered in patients with BMI <30 when cardiovascular risk is elevated and lifestyle intervention alone is insufficient" [12]. That language may support a prior authorization argument for patients just below the typical BMI cutoff.

Step 5: Use Your Telehealth Platform's Shortage Protocols

Programs like Calibrate have published shortage protocols that include pharmacy network switching, alternative drug referrals, and coaching-based strategies to minimize weight regain during gaps. If you are enrolled in a program, log into your patient portal and look for a shortage FAQ or contact your health coach directly. These programs often have pharmacy partnerships that give them earlier visibility into stock than individual patients checking their local drugstore.

What Calibrate Specifically Does During GLP-1 Shortages

Calibrate is a GLP-1-based metabolic health program that pairs medication with one-on-one coaching in food, sleep, exercise, and emotional health. The program's model is designed around the recognition that medication alone does not produce durable metabolic change; behavior change runs in parallel.

Calibrate's Shortage Response Framework

When a shortage affects a member's prescribed GLP-1, Calibrate's clinical team typically works through a tiered response:

1. Pharmacy network search. Calibrate partners with multiple pharmacy networks and can route prescriptions to pharmacies with current inventory before a member runs out.
2. Therapeutic substitution. If the original drug is unavailable across all partner pharmacies, the clinical team evaluates whether a different GLP-1 (e.g., switching from semaglutide to tirzepatide, or to liraglutide) is clinically appropriate for that member.
3. Compounded bridging (where legally permitted). During active FDA shortage designations, Calibrate has directed eligible members to 503B-accredited compounding pharmacies, with explicit counseling on the distinction between compounded and branded products.
4. Behavior-intensive gap support. When no pharmacologic option is immediately available, the coaching team increases check-in frequency and focuses on the four behavior pillars to slow potential weight regain.

This tiered approach reflects the broader evidence that behavior change reduces but does not eliminate weight regain during GLP-1 gaps. STEP-4 showed that even patients with strong behavioral support regained weight after stopping semaglutide [10], which is why pharmacologic continuity remains the first-line goal.

The Regulatory and Policy Context in 2025

The GLP-1 shortage situation is moving fast at the regulatory level, and staying oriented to the current rules matters.

FDA Shortage Database Status (Early 2025)

As of early 2025, tirzepatide injections are no longer listed as in shortage following the December 2024 FDA determination [5]. Semaglutide injection remains on the shortage list for certain dosage strengths; check the live FDA Drug Shortages database for current status [4]. Oral semaglutide (Rybelsus) has not been subject to the same shortages as the injectable form.

Compounding Enforcement Discretion

The FDA stated in 2024 that it would exercise enforcement discretion on compounded semaglutide through a defined wind-down period after the shortage designation ends, giving patients and programs time to transition to branded supply [9]. That discretion is not permanent. Compounding pharmacies that continue producing semaglutide or tirzepatide after shortage designation ends risk FDA enforcement action, and patients using those products after the wind-down period face an unregulated supply.

Legislative Activity

Several bills introduced in Congress between 2023 and 2024 proposed extending Medicare Part D coverage for obesity medications, which would dramatically expand GLP-1 access and potentially smooth demand spikes by bringing more patients into insured access rather than cash-pay gray markets. As of early 2025, no such bill has been signed into law, but CMS has signaled openness to reinterpreting existing coverage authority.

Monitoring Your Health During a Supply Gap

If a shortage forces a treatment gap, these are the specific markers worth tracking with your clinical team.

Body Weight

Weekly weights at the same time of day, under the same conditions, give the clearest signal of trajectory. A gain of more than 2 kg (roughly 4.4 lbs) over four weeks during a gap is a reasonable threshold for escalating contact with your prescriber.

Fasting Glucose and HbA1c (Diabetes Patients)

Patients using a GLP-1 for type 2 diabetes should check fasting glucose more frequently during a gap, particularly if not on a background medication. A fasting glucose above 180 mg/dL on two consecutive days warrants a call to your care team. HbA1c should be rechecked four to six weeks after any medication change.

Blood Pressure

GLP-1 receptor agonists produce modest blood pressure reductions. SUSTAIN-6 (N=3,297) showed systolic blood pressure reduction of 1.3 mmHg with semaglutide 1 mg versus placebo [13]. That effect reverses on discontinuation. Patients with baseline hypertension should monitor blood pressure weekly during a gap.